DMXE

coronary artery disease, heart failure, arrhythmias, hypertension

Tachycardia, hypertension, and ECG abnormalities (including ST-segment elevation and sinus bradycardia) are documented class-level effects of arylcyclohexylamines. MXE case data (Imbert et al. 2014) demonstrated significant cardiovascular disturbance during acute intoxication. Individuals with pre-existing cardiovascular disease face elevated risk.

epilepsy, febrile seizure history, seizure disorder

Seizures have been documented in acute MXE intoxication, presenting alongside cardiovascular abnormalities (Imbert et al. 2014). NMDA antagonists can lower seizure threshold through preferential blockade of inhibitory interneuron NMDA receptors, leading to cortical disinhibition. Individuals with epilepsy or other seizure disorders face elevated risk.

schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, family history of psychotic disorders

Individuals with a personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features) face elevated risk of prolonged psychotomimetic effects from NMDA receptor antagonists. Substance-induced psychotic disorder with bilateral DLPFC metabolic deficit has been documented for MXE (Moccia et al. 2019), and persistent psychosis after 3-MeO-PCP use (Pepe et al. 2024). DMXE shares the same primary mechanism and chemical class.

cirrhosis, hepatitis, severe hepatic impairment

DMXE's metabolism is predicted to rely on hepatic CYP2B6 and CYP3A4 enzymes (inferred from MXE metabolism data, Meyer et al. 2013). Individuals with hepatic impairment may experience reduced clearance, prolonged drug action, and increased risk of adverse effects due to elevated plasma concentrations.

chronic kidney disease, acute kidney injury history, renal transplant

Renal impairment may reduce clearance of DMXE and its metabolites, leading to unpredictable drug accumulation. Additionally, the first laboratory-confirmed case of 3-methyl-PCP use (which shares DMXE's 3-methylphenyl ring substitution) produced rhabdomyolysis and acute kidney injury (Deutsch et al. 2026). This structural parallel warrants caution in individuals with pre-existing renal compromise.

pregnancy, planned pregnancy

NMDA receptor-mediated glutamatergic signaling plays a critical role in neuronal migration, synaptogenesis, and neurodevelopment. Blockade of NMDA receptors during gestation may disrupt these processes. No reproductive toxicity data exist for DMXE in any species. This contraindication is based on mechanistic inference from NMDA receptor biology.

MAO-A inhibitor use, MAO-B inhibitor use, non-selective MAOI use

Concurrent use of monoamine oxidase inhibitors (MAOIs) with DMXE is contraindicated due to the risk of potentiated serotonergic and sympathomimetic effects. MXE, DMXE's parent compound, possesses appreciable SERT affinity. Whether DMXE retains this property is uncharacterized, but the combination is mechanistically dangerous. Community reports strongly advise against MAOI + arylcyclohexylamine combinations.

high-dose SSRI use, high-dose SNRI use, venlafaxine, duloxetine

Co-administration of DMXE with high-dose SNRIs or SSRIs carries risk of serotonin syndrome if DMXE possesses serotonin transporter (SERT) activity analogous to its parent compound MXE. A fatal case involving O-PCE (which shares DMXE's ethylamino group and cyclohexanone core) combined with the SNRI venlafaxine (femoral blood 375 μg/L) underscores this concern. DMXE's SERT activity has not been measured.

interstitial cystitis, bladder inflammation, urinary tract obstruction, reduced bladder capacity

Chronic heavy ketamine use causes ketamine-induced uropathy (KIU), a progressive lower urinary tract syndrome characterized by inflammation, fibrosis, reduced bladder capacity, and in severe cases ureteral stenosis and renal failure (Castellani et al. 2020). Whether DMXE carries the same bladder toxicity risk is unknown, but this is a class-level concern. Individuals with pre-existing lower urinary tract disease face elevated risk of exacerbation with repeated DMXE exposure.